|
MechanismVEGFR antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
重组人内皮抑素腺病毒注射液联合化疗治疗晚期头颈部恶性肿瘤的多中心、随机对照II期临床试验
[Translation] A multicenter, randomized, controlled phase II clinical trial of recombinant human endostatin adenovirus injection combined with chemotherapy in the treatment of advanced head and neck malignancies
评价重组人内皮抑素腺病毒注射液联合化疗治疗晚期头颈部恶性肿瘤的抗肿瘤疗效和安全性
[Translation] To evaluate the anti-tumor efficacy and safety of recombinant human endostatin adenovirus injection combined with chemotherapy in the treatment of advanced head and neck malignancies
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
100 Clinical Results associated with Chengdu Shi Endor Biological Engineering Technology Co., Ltd
0 Patents (Medical) associated with Chengdu Shi Endor Biological Engineering Technology Co., Ltd
100 Deals associated with Chengdu Shi Endor Biological Engineering Technology Co., Ltd
100 Translational Medicine associated with Chengdu Shi Endor Biological Engineering Technology Co., Ltd